---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-22-000005"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2022-01-12T23:59:59+00:00"
generated_at: "2026-06-27T18:30:47.742549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q4 rev $2.74B (-9% YoY); FY EPS beats outlook; 2022 guidance raised

## Summary
- Preliminary Q4 2021 revenue ~$2.74B, down 9% from $3.00B in Q4 2020.
- Q4 reported diluted EPS $3.12; adjusted diluted EPS $3.33 (vs $4.48 adjusted in Q4 2020).
- Full year 2021 revenue ~$10.79B (+14% YoY); adjusted diluted EPS $14.24 exceeded prior outlook.
- COVID-19 testing demand higher than expected; Q4 included 7.9M molecular tests and 0.7M serology tests.
- 2022 guidance raised: now expects adjusted diluted EPS above $8.00 (prior was near upper end of $7.40-$8.00).

## SEC filing metadata
- accession: 0001022079-22-000005
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2022-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000005/0001022079-22-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000005/dgx-20220112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-22-000005
- JSON: https://secwatch.observer/filing/0001022079-22-000005.json
- Plain text: https://secwatch.observer/filing/0001022079-22-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.